Bayer, Nuvisan to create drug discovery research unit in Berlin

NUVISAN has agreed with Bayer to integratelarge partsof Bayer’s Berlin-based small molecule research unit and complementshereby its services in the field of preclinical research. NUVISAN is an international service provider for clinical studies, laboratory services and contract manufacturing (CRO / CDMO) with several sites and clinics in Germanyand France. The strategic partnership willlay the foundation for a new research entity to be established by NUVISAN in Berlin and confirms the longstanding cooperation between the two companies.

“With NUVISANwe have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development. “NUVISANshares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists”.

The partnered Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research center comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics and Investigational Toxicology.

“With these new drug discovery capabilities and capacitiesin the field of drug discovery, we do not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technologyand continuously expand the range of services,” says Dr. Dietrich Bruchmann, CEO and managing partner of NUVISAN. “The acquisition of the research unit and our commitment to the locationat the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow the combined businesses to significantly accelerate the drug development process from discovery to clinical trials.There is hardly any overlap in our range of services, so that we can immediately benefit from a variety of synergies and operational advantages through the new research center.”

NUVISAN and Bayerwill cooperate closely in the coming years to build the new research center. The transaction is expected to close mid of 2020. Financial terms were not disclosed

About NUVISAN

The NUVISANgroup generates sales of approx. € 55 million with currently about 420 highly qualified employees. It originated from LAB GmbH over 40 years ago and has been operating under the name NUVISAN with its headquarters in Neu-Ulm since 2010. The NUVISANgroup as a Clinical Research Organization (CRO) and Contract Manufacturing Organization (CDMO) has six sites in Germany and France (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop and Sophia-Antipolis) in addition to monitoring activities with offices in Argentina, Peru and Brazil as well as in the USA.For more information, go to www.nuvisan.com

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.